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Abstract 
Background: Gut microbiota is now known to control glucose metabolism. Previous studies have shown that probi-
otics and prebiotics may improve glucose metabolism, but their effects have not been studied in combination with 
drug therapy. The aim of this study was to investigate whether probiotics and prebiotics combined with drug therapy 
affect diabetic outcomes.
Methods: Two different study designs were used to test gut microbiota modulating treatments with metformin 
(MET) or sitagliptin (SITA) in male C57Bl/6J mice. In Design 1, diabetes was induced with four-week feeding with 
a ketogenic, 72 kcal% fat diet with virtually no carbohydrates. Mice were then randomly divided into four groups 
(n = 10 in each group): (1) vehicle, (2) Bifidobacterium animalis ssp. lactis 420 (B420) (109 CFU/day), (3) MET (2 mg/
mL in drinking water), or (4) MET + B420 (same doses as in the MET and B420 groups). After another 4 weeks, glu-
cose metabolism was assessed with a glucose tolerance test. Fasting glucose, fasting insulin and HOMA-IR were 
also assessed. In Design 2, mice were fed the same 72 kcal% fat diet to induce diabetes, but they were simultane-
ously treated within their respective groups (n = 8 in each group): (1) non-diabetic healthy control, (2) vehicle, (3) 
SITA [3 mg/(kg*day)] (4) SITA with prebiotic polydextrose (PDX) (0.25 g/day), (5) SITA with B420 (109 CFU/day), and 
(6) SITA + PDX + B420. Glucose metabolism was assessed at 4 weeks, and weight development was monitored for 
6 weeks.
Results: In Design 1, with low-dose metformin, mice treated with B420 had a significantly lower glycemic response 
(area under the curve) (factorial experiment, P = 0.002) and plasma glucose concentration (P = 0.02) compared to 
mice not treated with B420. In Design 2, SITA + PDX reduced glycaemia in the oral glucose tolerance test significantly 
more than SITA only (area under the curve reduced 28 %, P < 0.0001). In addition, B420, PDX or B420+PDX, together 
with SITA, further decreased fasting glucose concentrations compared to SITA only (−19.5, −40 and −49 %, respec-
tively, P < 0.01 for each comparison). The effect of PDX may be due to its ability to increase portal vein GLP-1 concen-
trations together with SITA (P = 0.0001 compared to vehicle) whereas SITA alone had no statistically significant effect 
compared to vehicle (P = 0.14).
Conclusions: This study proposes that combining probiotics and/or prebiotics with antidiabetic drugs improves 
glycemic control and insulin sensitivity in mice. Mechanisms could be related to incretin secretion.
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Background
In recent years, the understanding of the link between gut 
microbiota and metabolic disease has rapidly increased. 
Various metabolic disorders have been linked to the gut 
microbiota through a common mechanism: metabolic 
endotoxaemia-induced inflammation [1]. In both animals 
[2–4] and humans [5] glucose metabolism disorders have 
been related to increased permeability of the gut bar-
rier, which leads to increased translocation of endotoxins 
and even translocation of commensal bacteria [6]. These 
translocated bacteria form a so-called tissue microbiota 
[7], which evokes tissue inflammation [8] and, eventually, 
metabolic disorders [7, 9].
Since the first findings of a modified gut microbiota 
in obese mice and humans [10, 11], there has been an 
increasing recognition of the importance of gut micro-
bial composition in metabolic health [12, 13]. Given the 
close relationship between the different components of 
metabolic syndrome, it has been difficult to pin-point 
specific species of bacteria that influence glucose metab-
olism or insulin resistance. Furthermore, methodological 
differences, high inter-individual variance and conflict-
ing results have made it impossible to draw definitive 
conclusions on which species are altered [14]. However, 
decreased gut microbial diversity has been suggested to 
play a role in the development of metabolic disorders—
a large study of approximately 300 participants showed 
that decreased gut microbial diversity is related to an 
unfavorable shift in the markers of glucose metabolism 
and low-grade inflammation [15]. When gut microbial 
diversity is improved with a dietary regimen, insulin sen-
sitivity is also improved [16, 17]. Despite the lack of infor-
mation regarding the specific gut microbial alterations 
impairing glucose metabolism, a landmark study using 
fecal transplantations presented preliminary but encour-
aging evidence of a causal relationship between gut 
microbes and glucose metabolism in humans [18]. Feces 
were transferred from healthy lean donors to male recipi-
ents with metabolic syndrome and, strikingly, the treat-
ment improved the insulin sensitivity of the recipients.
The revelation of the involvement of gut microbiota has 
led to intense research on how to utilize this link to treat 
diabetes. Thus, several bacterial strains and dietary fibers 
have been tested for an effect on glucose metabolism [2, 
17, 19–23]. We have previously shown that Bifidobacte-
rium animalis ssp. lactis 420 improves insulin sensitiv-
ity and glucose tolerance while decreasing fat mass in 
dietary mouse models of diabetes and obesity [6, 24]. The 
treated mice also showed reduced tissue inflammation 
and endotoxaemia compared to the controls. Polydex-
trose, on the other hand, has been shown to induce satia-
tion [25], ameliorate glycemic response [26] and reduce 
LDL cholesterol [27] in humans, pointing at a possible 
benefit in weight maintenance and metabolic health.
Currently, type 2 diabetes is primarily treated with drug 
therapy, such as the first line treatment metformin, with 
or without gliptins or sulfonylureas. Similar to all drugs, 
these treatments come with certain side effects. This 
fact is particularly true for metformin because approxi-
mately 30 % of patients must discontinue or dramatically 
reduce their daily therapeutic doses due to diarrheas. The 
dose reduction hampers the anti-diabetic efficacy of the 
treatment [28]. Dual treatments may be used to either 
improve the efficacy of the treatment or to reduce the 
dosage of an individual drug to prevent the occurrence of 
side effects.
The objective of this study was to test whether B420 
and a dietary fiber, polydextrose (PDX) could improve 




Male C57Bl/6J mice were obtained from Charles River 
(L’Arbresle, France) and acclimatized for at least 7  days 
prior to any experimentation. The mice were housed in 
groups of 4–6 animals per cage and maintained under 
a normal dark-light cycle (12  h/12  h), 22  ±  2  °C and 
55  ±  10  % relative humidity. Tap water and feed were 
provided ad libitum. At 8–10 weeks of age, the mice were 
subjected to one of the two study designs outlined below.
Design 1 First, we investigated the ability of B420 to 
potentiate the antidiabetic effect of metformin in diabetic 
mice. Metformin was used at a minimally active dose to 
ensure that the synergistic effect of the probiotic treat-
ment on the antidiabetic drug could be tested. Diabetes 
was induced during a four-week feeding period with a 
ketogenic, 72 energy% fat diet, with 28 energy% protein 
and <1 energy% carbohydrate (UAR, France). This diet 
has been previously shown to increase fasting plasma glu-
cose concentrations, impair glucose tolerance and lead to 
insulin resistance after only 4 weeks of feeding [29]. After 
the diabetes induction period, the mice were randomly 
allocated into groups. They were first ranked according 
to the value of the AUC of the intra-peritoneal glucose 
tolerance test (IPGTT) and then allocated sequentially to 
the different groups. This method ensures that all groups 
are characterized by a similar AUC of IPGTT. The val-
ues were confirmed by comparing body weight, IPGTT’s 
AUC, and plasma glucose and insulin concentrations. 
The average plasma glucose after the induction period 
was 9.18 ±  0.29  mmol/L, and there were no significant 
between-group differences. The experimental groups 
were as follows: (1) vehicle, diabetic controls with a daily 
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gavage of saline; (2) B420, Bifidobacterium animalis ssp. 
lactis 420 (DuPont N&H), 109 CFU gavaged daily; (3) 
MET, metformin (Sigma), 2 mg/mL in drinking water was 
used at a dose inducing minimal or no antidiabetic effect; 
and (4) MET +  B420, 2  mg/mL metformin in drinking 
water and 109 CFU B420 gavaged daily. There were ten 
mice in each group. The glucose metabolism parameters 
were measured after 4 weeks of treatment. The primary 
outcome was the AUC in the IPGTT test. The second-
ary outcomes were fasting plasma glucose, fasting plasma 
insulin and HOMA-IR (Homeostatic model assessment 
of insulin resistance) levels. HOMA-IR was calculated as: 
[Glucose] × [Insulin]/22.5.
Design 2 Next, the effects of gut microbiota–modu-
lating treatments combined with sitagliptin were stud-
ied in a prevention model to better distinguish between 
the vehicle and sitagliptin groups. The mice were first 
ranked according to their bodyweight and then randomly 
assigned into six groups; diabetes was induced simulta-
neously with the treatment regimens that were gavaged 
daily. In addition to B420, we now included a prebiotic, 
polydextrose (PDX), because of its promising results 
on satiety and metabolism in human studies [25–27]. A 
non-diabetic control group was added to better evalu-
ate the magnitude of the effect, since our laboratory had 
less experience of the prevention model than the treat-
ment model in Design 1, which we had developed our-
selves. The following groups were established (n =  8 in 
each group): (1) NFD, healthy non-diabetic controls 
on a normal-fat diet; (2) vehicle, diabetic mice gavaged 
daily with saline; (3) SITA, sitagliptin, 3  mg/(kg*day); 
(4) SITA + PDX, sitagliptin with Litesse® Ultra polydex-
trose, 0.25 g/day; (5) SITA + B420, sitagliptin with B420 
109 CFU/day; and (6) SITA + PDX + B420 (as described 
above). Groups 2–6 continued on the ketogenic diet 
throughout the study. At 4  weeks, blood samples were 
drawn, and an IPGTT was performed. To monitor body 
weight and to reduce the effects of treatment and han-
dling on the final samples, the mice were followed-up for 
two more weeks before being sacrificed. Ileum, pancreas 
and portal vein blood were harvested for further analysis. 
The primary outcome was the AUC in the IPGTT test. 
The secondary outcomes were fasting plasma glucose, 
fasting plasma insulin, HOMA-IR, portal vein GLP-1, 
ileal tissue GLP-1 and serum DPP-4 activity.
During both experimental designs, body weight was 
monitored weekly. All procedures were performed in 
accordance with the Guide for the Care and Use of Labo-
ratory Animals (revised 1996) and French laws.
Glucose tolerance tests
Glucose-tolerance tests were performed after four 
(Design 1) or six (Design 2) weeks of treatment to assess 
glucose management in mice. In Design 1 mice fasted for 
6  h were injected with glucose (1  g/kg) into the perito-
neal cavity to assess the overall antidiabetic effect of met-
formin. In Design 2, oral glucose tolerance tests (glucose 
2 g/kg) were performed to assess the potentiation of the 
incretin effect of sitagliptin on glycaemia. The glucose 
response was followed from 30  min before the glucose 
challenge until 120  min after the challenge, measuring 
plasma glucose every 15–30  min using a standard glu-
cose meter (Roche Diagnostics, Basel, Switzerland). The 
area under the curve was calculated from 0 to 120 min as 
the geometrical area between zero and the blood glucose 
curve for each individual mouse.
Biochemistry
Blood samples for insulin assays were collected after 
4 weeks of treatment from the tail veins of mice fasted for 
6 h. Fasted plasma insulin was measured with an ELISA 
kit (#10-1247-01, Mercodia AB, Uppsala, Sweden).
In Design 2, ileum and portal blood were collected 
upon sacrifice from the mice under fed conditions. 
Plasma was collected in the presence of a DPP-4 inhibi-
tor (0.1  mM diprotine A, Bachem, Switzerland), imme-
diately centrifuged and the plasma separated and kept 
frozen at −80 °C. The plasma active GLP-1 concentration 
was measured with ELISA from 100 µl of plasma (GLP-1 
active 7-36, Alpco, NH, USA). The lower limit of detec-
tion was between 0.5 and 1 pM. Ileum samples were lysed 
in buffer containing 70  % ethanol (v/v) and 0.1  M HCl. 
The extracts were diluted 1/10,000 to 1/100,000. GLP-1 
concentrations were then measured with an ELISA kit 
(#43-GP1HU-E01, Eurobio, Courtaboeuf, France). DPP-4 
was analyzed from portal blood with a luminescent pro-
tease assay (#G8350, Promega, Madison, Wisconsin, 
USA) in order to confirm the efficacy of SITA, which is a 
DPP-4 inhibitor.
Statistical analysis
Data were analyzed using GraphPad Prism 6 (GraphPad 
Software Inc., California, USA) and R: A Language and 
Environment for Statistical Computing, version 3.1.2 
(http://www.R-project.org/).
In Design 1 the study was performed in a 2 × 2 setting 
with two factors: MET and B420. Normality and equal-
ity of group variances were first assessed with Shapiro–
Wilk test and Brown-Forsythe test. If the data were found 
unsuitable for parametric analyses directly, a logarithmic, 
square root or inverse transformation was applied to all 
data of the same biomarker in order to analyze the data 
parametrically. The statistical analysis was then per-
formed as a 2x2 factorial analysis that gives p-values for 
the main effects of B420, MET, and their interaction. For 
the IPGTT test, one value from the 60-min time point 
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was missing in the B420 group and, as a conservative 
approach, the value from the 30-min time point was used 
to calculate the AUC.
In Design 2 we applied the same data transformations 
as in Design 1 for consistency. After the transformations 
all data were found suitable for parametric analyses. Most 
data were analyzed with one-way ANOVA. Supplemental 
data were analyzed with two-way ANOVA. If the global 
P was significant, Tukey’s HSD test was used to assess 
between-group differences. All data are expressed as the 
mean ± standard error of mean (SEM), and significances 
are two-sided. Differences were considered to be statisti-
cally significant when P < 0.05.
Results
Pro‑ and prebiotics improve glucose regulation 
during anti‑diabetic treatment
At the dose used in this design metformin demonstrated 
no effect on glucose tolerance in mice on a ketogenic diet 
(Fig. 1A, B) (P = 0.18). However, the B420-treated mice 
showed better glucose tolerance than those who were 
not treated with B420 (B420: AUC 2140  ±  93  mmol/
L*min, MET + B420: 2160 ± 116 mmol/L*min, vehicle: 
2340 ± 107 mmol/L*min, MET: 2660 ± 99 mmol/L*min, 
P = 0.002). No interactions were detected between MET 
and B420. Due to injection failures, IPGTT could not be 
performed to one mouse in the Vehicle group, two in the 
MET group and one in the B420 group.
In the sitagliptin design, the SITA mice demonstrated 
better glucose tolerance than the diabetic vehicle–mice 
(1250  ±  18  mmol/L*min vs. 1420  ±  42  mmol/L*min, 
P  =  0.008) (Fig.  1C, D). The SITA  +  PDX and 
SITA  +  PDX  +  B420 mice showed further improved 
glucose tolerance compared to the SITA mice 
(894 ±  34  mmol/L*min and 798 ±  35  mmol/L*min for 
SITA  +  PDX and SITA  +  PDX  +  B420, respectively, 
both P  <  0.0001 compared to SITA). SITA  +  B420 
(1140 ±  28  mmol/L*min) showed no additional benefit 
compared to SITA (P = 0.24).
Body weight gain was also significantly reduced in the 
MET + B420 group compared to vehicle, as well as the 
SITA + PDX and SITA + PDX + B420 groups compared 
to SITA or vehicle (P < 0.05 for all comparisons) (Addi-
tional file 1: Figure S1). Metformin and sitagliptin alone 
had no effect on body weight.
Fasting glucose, insulin and HOMA‑IR
At this low dose, metformin had no significant effect on 
fasting glucose, but mice treated with MET had lower 
plasma insulin concentrations (MET: 12.5  ±  0.61 µU/
mL, MET + B420: 11.4 ± 1.5 µU/mL, vehicle: 21.1 ± 3.8 
µU/mL, B420: 19.4 ± 2.3 µU/mL, P = 0.004) and a lower 
HOMA-IR (MET: 6.27  ±  0.41 units, MET  +  B420: 
5.07  ±  0.61 units, vehicle: 10.0  ±  1.7 units, B420: 
8.61  ±  1.2 units, P  =  0.003) than those who were not 
treated with MET (Fig.  2A–C). Mice treated with B420 
had a significantly lower concentration of plasma 
glucose (B420: 9.77  ±  0.31  mmol/L, MET  +  B420: 
10.3 ± 0.63 mmol/L, vehicle: 10.8 ± 0.33 mmol/L, MET: 
11.4  ±  0.40  mmol/L, P  =  0.02) than those not treated 
with B420, but there was no effect on plasma insulin or 
HOMA-IR. No interactions were detected between MET 
and B420. Due to technical difficulties, glucose could not 
be assessed from one mouse in the MET group, and insu-
lin could not be assessed from one mouse in the B420 
group and one in the MET group. These are reflected 
in the numbers of mice that could be included in the 
HOMA-IR calculations.
Sitagliptin had no significant effect on fasting 
glucose, insulin or HOMA-IR (Fig.  2D–F). How-
ever, all treatment groups with PDX and B420 
showed lower fasting blood glucose than the vehi-
cle and SITA groups (vehicle 8.3 ±  0.43  mmol/L, SITA 
8.7  ±  0.42  mmol/L, SITA  +  PDX 5.2  ±  0.22  mmol/L, 
SITA + B420 7.0 ± 0.22 mmol/L, SITA + PDX + B420 
4.4 ± 0.18 mmol/L, P < 0.01 for all SITA vs. treatments) 
(Fig.  2D). There were no differences between groups in 
fasting plasma insulin. However, HOMA-IR was signifi-
cantly lower in the SITA + PDX + B420 group than both 
the vehicle and SITA groups (vehicle 5.4  ±  0.42, SITA 
5.6  ±  3.5, SITA  +  PDX  +  B420 2.2  ±  0.49, P  <  0.001 
compared to both vehicle and SITA).
GLP‑1 release
To elucidate possible mechanisms, we investigated 
whether the selected gut microbiota modulators affect 
GLP-1 secretion from the gut; therefore, GLP-1 was 
measured from ileum and portal vein (Fig.  3A, B). The 
SITA + PDX and the SITA + PDX + B420 groups both 
showed a higher portal vein concentration of GLP-1 
than the vehicle group (vehicle 4.9  ±  0.65  pmol/L, 
SITA +  PDX 20.8 ±  4.3  pmol/L, SITA +  PDX +  B420 
21.5 ± 5.3 pmol/L, P = 0.0001 for both groups vs. vehi-
cle), whereas the SITA group did not significantly differ 
from vehicle (SITA 11.3 ± 3.6 pmol/L, P = 0.14 vs. Vehi-
cle), nor did SITA + B420 (7.4 ± 1.6 pmol/L, P = 0.76). 
Due to technical issues, portal vein GLP-1 could not be 
measured from one mouse in the SITA + B420 group.
Ileal GLP-1 was not significantly increased by sit-
agliptin (vehicle 24,900  ±  2100  pmol/L, SITA 
32,700 ±  2600  pmol/L, P =  0.26) (Fig.  3B). In contrast 
to what was observed for portal GLP-1 concentrations, 
only the SITA + B420 group had a higher level of ileum 
GLP-1 than the vehicle group (38,700  ±  2400  pmol/L, 
P = 0.006). None of the PDX treatment groups differed 
from vehicle.
Page 5 of 9Stenman et al. Diabetol Metab Syndr  (2015) 7:75 
To confirm efficacy of sitagliptin, we then measured 
the concentration of DPP-4 from portal vein. The SITA 
group had 91  % lower DPP-4 activity than the vehicle 
group, and activity was 93 % lower in the PDX and B420 
treatment groups (P  <  0.001 for all groups with SITA 
compared to NFD or vehicle). There were no statistically 
significant differences between the SITA groups.
Discussion
In the present study, a potential probiotic B420 and/
or Litesse® Ultra polydextrose were used together with 
metformin or sitagliptin to treat diabetes in mice. To our 
knowledge, this study is the first to demonstrate addi-
tional benefits for probiotic and prebiotic products on 




































































































n=9 n=9 n=8 n=10
MET: P = 0.18
B420:P = 0.002
MET*B420:P = 0.17
Fig. 1 Glucose tolerance of mice after 4 weeks of treatment. Intraperitoneal glucose tolerance (A) and area under the curve (AUC) (B) of mice 
treated with metformin (MET) and/or Bifidobacterium animalis ssp. lactis 420 (B420) while on a high-fat diet. The oral glucose tolerance (C) and AUC 
(D) of mice treated with sitagliptin (SITA), polydextrose (PDX) and/or B420 while on a high-fat diet, in contrast to mice on a normal-fat diet (NFD). All 
data are expressed as the mean ± SEM. Groups without common letters differ significantly from one another (p < 0.05)










































































































































Fig. 2 Fasted glucose (A, D), insulin (B, E) and HOMA-IR (C, F) after 4 weeks of treatment with metformin (MET), sitagliptin (SITA), polydextrose 
(PDX) and/or Bifidobacterium animalis ssp. lactis 420 (B420) in mice on a high-fat diet, in contrast to mice on a normal-fat diet (NFD). All data are 
expressed as the mean ± SEM. Groups without common letters differ significantly from one another (p < 0.05)
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Metformin is used as the primary treatment for type 2 
diabetes, and numerous specific mechanisms have been 
described. However, numerous mechanisms still remain 
to be uncovered. Metformin is known to increase the 
activation of AMP activated protein kinase (AMPK), 
an important enzyme for cellular energy homeostasis 
[30]. In the liver, AMPK activation leads to improved 
insulin receptor function and, thus, improved glucose 
transport, as well as reduced fatty acid synthesis. More 
recently, metformin has been shown to directly regu-
late gut microbiota metabolism; most notably, it affects 
the microbial methionine and folate metabolism [31]. 
The importance of metformin’s effect on gut microbiota 
was also demonstrated through its impact on the prolif-
eration of Akkermansia [32]. In the latter case, when used 
as a prebiotic, metformin was shown to impact energy 
metabolism [33], and it was suggested that the beneficial 
effect of the antidiabetic drug does include the treatment 
of gut dysbiosis in type 2 diabetic patients [34]. Together, 
these molecular mechanisms lead to improved insulin 
sensitivity. In the present study we used a low dose of 
MET in order to see if MET combined with B420 could 
improve diabetes-related outcomes with a reduced risk 
of adverse effects. There were reduced plasma insu-
lin concentrations and HOMA-IR levels in the groups 
treated with MET compared to those not treated with 
MET. B420 had no additional benefit on plasma insu-
lin compared to metformin only, but B420 significantly 
attenuated the glucose response in IPGTT and decreased 
fasting plasma glucose concentration, suggesting that a 
combination treatment could be more effective in treat-
ing diabetes than metformin alone.
Sitagliptin, similar to all other gliptins, is an inhibitor 
of the enzyme DPP-4 a proconvertase that inactivates the 
incretins GLP-1 and gastric inhibitory peptide (GIP) by 
removing the first two N-terminal amino acid residues 
[35]. With this inactivation, sitagliptin increases the con-
centration of active incretins [36], which enhances glu-
cose-induced insulin secretion and thereby improves oral 
glucose tolerance as reported in the present study. Only 
the groups treated with PDX showed further improved 
glucose tolerance compared to the SITA group. Sitag-
liptin had no effect on fasting glucose and insulin levels. 
Interestingly, however, B420 and PDX, as well as their 
combination, decreased the fasting concentration of 
plasma glucose compared to the vehicle and sitagliptin 
treatments. Together, B420 and PDX decreased HOMA-
IR compared to sitagliptin only, although this effect 
seems to be purely due to the reduced fasting plasma glu-
cose concentration.
As expected, all groups treated with SITA displayed 
minimal activity of DPP-4, the enzyme that SITA selec-
tively inhibits. Consequently, SITA group had a slightly 
higher portal vein GLP-1 concentration compared to 





































































Fig. 3 Portal vein (A) and ileal (B) GLP-1 concentrations and serum 
DPP-4 activity (C) after 6 weeks of treatment with sitagliptin (SITA), 
polydextrose (PDX) and/or Bifidobacterium animalis ssp. lactis 420 
(B420) in mice on a high-fat diet, in contrast to mice on a normal-fat 
diet (NFD). All data are expressed as the mean ± SEM. Groups with-
out common letters differ significantly from one another (p < 0.05)
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Surprisingly, we showed that PDX promotes GLP-1 
release into portal blood. GLP-1 treatment in humans 
decreases plasma glucose concentration without directly 
improving insulin sensitivity as assessed by hyperin-
sulinaemic clamp measurement [37]. Thus the impact 
of PDX on the glycemic control by sitagliptin could be 
mediated through GLP-1 release, which might be a plau-
sible mechanism for the effect of PDX on fasting glucose.
B420 did not increase the portal blood GLP-1 concen-
tration, but it did significantly increase the ileum GLP-1 
concentration compared to the vehicle group, suggest-
ing that whereas the tissue concentration of GLP-1 was 
enhanced by the probiotic, a further signal was perhaps 
required to trigger the peptide release into the circula-
tion. The molecular mechanisms by which B420 could 
reduce glycaemia and fasting blood glucose concentra-
tions could not be determined in this study. Neverthe-
less, several pieces of evidence indicate that B420 could 
improve gut barrier function [24, 38], and B420 is known 
to reduce tissue inflammation in mice on a high-fat diet 
[6, 24]. These key mechanisms control insulin resistance 
in type 2 diabetes and may explain the reduced fast-
ing plasma glucose level demonstrated in this study. We 
recently showed that the combination of B420 and PDX 
normalized insulin resistance while preventing the high-
fat diet-related decrease in Th17 and Treg cells in the ileal 
lamina propria [39].
The effect of B420 on glucose metabolism has been 
greater in previously published studies [6, 24]. Although 
these two previous studies were performed by the same 
research group, they were conducted at a different ani-
mal facility than the experiments in the present study. 
There are several factors that may cause differing results 
between laboratories, such as differences in the microbial 
environment, different animal handling practices, and 
factors related to the origin of the animals; note that the 
litter size of an individual mouse impacts its tendency to 
gain weight [40]. A small litter size results in so-called 
postnatal overfeeding, which results in obesity, insulin 
resistance, and glucose intolerance, which can even carry 
over to the offspring [41]. As long as these issues cannot 
be controlled between experiments, the exact replication 
of previously published study designs remains difficult.
In conclusion, both the probiotic and the prebiotic 
showed benefits to glycemic response and fasting plasma 
glucose but not fasting plasma insulin in mice. Whereas 
the low dose of metformin alone reduced plasma insu-
lin concentration, the probiotic showed a complemen-
tary effect by lowering plasma glucose levels. Compared 
to sitagliptin only, polydextrose further decreased the 
oral glucose tolerance test response. In addition, fast-
ing glucose was not affected by sitagliptin, whereas 
polydextrose, B420 and their combination all induced a 
significant decrease, although the polydextrose group 
showed the most marked improvement. The effect of 
polydextrose seems to be at least partly mediated through 
an increased concentration of portal GLP-1. The present 
study proposes a benefit for combining probiotics and/or 
prebiotics with antidiabetic drugs, this finding should be 
further assessed in clinical trials.
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